SG175680A1 - Cancer susceptibility variants on chr8q24.21 - Google Patents

Cancer susceptibility variants on chr8q24.21 Download PDF

Info

Publication number
SG175680A1
SG175680A1 SG2011078417A SG2011078417A SG175680A1 SG 175680 A1 SG175680 A1 SG 175680A1 SG 2011078417 A SG2011078417 A SG 2011078417A SG 2011078417 A SG2011078417 A SG 2011078417A SG 175680 A1 SG175680 A1 SG 175680A1
Authority
SG
Singapore
Prior art keywords
cancer
allele
marker
markers
prostate cancer
Prior art date
Application number
SG2011078417A
Other languages
English (en)
Inventor
Julius Gudmundsson
Patrick Sulem
Augustine Kong
Andrei Manolescu
Laufey Amundadottir
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Publication of SG175680A1 publication Critical patent/SG175680A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG2011078417A 2006-10-27 2007-10-26 Cancer susceptibility variants on chr8q24.21 SG175680A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IS8560 2006-10-27

Publications (1)

Publication Number Publication Date
SG175680A1 true SG175680A1 (en) 2011-11-28

Family

ID=39060300

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011078417A SG175680A1 (en) 2006-10-27 2007-10-26 Cancer susceptibility variants on chr8q24.21

Country Status (13)

Country Link
US (1) US20100129799A1 (enExample)
EP (1) EP2089548A1 (enExample)
JP (1) JP5631000B2 (enExample)
CN (1) CN101641451A (enExample)
AU (1) AU2007310412B2 (enExample)
BR (1) BRPI0718322A2 (enExample)
CA (1) CA2667737A1 (enExample)
IL (1) IL198305A0 (enExample)
MX (1) MX2009004522A (enExample)
NZ (1) NZ576591A (enExample)
SG (1) SG175680A1 (enExample)
WO (1) WO2008050356A1 (enExample)
ZA (1) ZA200903173B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
CA2677994A1 (en) * 2007-02-07 2008-08-14 Decode Genetics Ehf. Genetic variants contributing to risk of prostate cancer
SG177960A1 (en) 2007-04-17 2012-02-28 Santen Pharmaceutical Co Ltd Method for determination of onset risk of glaucoma
US8697360B2 (en) * 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
US20090226912A1 (en) * 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
AU2009269542A1 (en) * 2008-07-07 2010-01-14 Decode Genetics Ehf Genetic variants for breast cancer risk assessment
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP3075864A1 (en) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP2451975A4 (en) * 2009-05-08 2013-08-14 Decode Genetics Ehf GENETIC VARIANTS CONTRIBUTING TO A RISK OF PROSTATE CANCER
WO2011004404A1 (en) * 2009-07-10 2011-01-13 Decode Genetics Ehf Genetic variants for predicting risk of glaucoma
WO2011009089A1 (en) * 2009-07-17 2011-01-20 Ordway Research Institute, Inc. SMALL NON-CODING REGULATORY RNAs AND METHODS FOR THEIR USE
US20120316218A1 (en) * 2009-07-17 2012-12-13 Glinsky Gennadi V SMALL NON-CODING REGULARTORY RNA's and METHODS FOR THEIR USE
CN102656458B (zh) 2009-10-26 2016-10-19 雅培分子公司 用于测定非小细胞肺癌预后的诊断方法
TW201120449A (en) 2009-10-26 2011-06-16 Abbott Lab Diagnostic methods for determining prognosis of non-small-cell lung cancer
WO2012029080A1 (en) * 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
US9732389B2 (en) 2010-09-03 2017-08-15 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
KR20130113447A (ko) 2010-09-24 2013-10-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화
US9534256B2 (en) 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
EP2673380B1 (en) * 2011-02-09 2018-12-12 Bio-Rad Laboratories, Inc. Analysis of nucleic acids
CN102304567B (zh) * 2011-04-29 2013-03-27 广州益善生物技术有限公司 一种染色体8q24区段多态性检测特异性引物和液相芯片
US10233502B2 (en) 2011-06-22 2019-03-19 Indiana University Research And Technology Corporation Compositions for and methods of detecting, diagnosing, and prognosing thymic cancer
WO2013065072A1 (en) * 2011-10-30 2013-05-10 Decode Genetics Ehf Risk variants of prostate cancer
US9944998B2 (en) 2013-07-25 2018-04-17 Bio-Rad Laboratories, Inc. Genetic assays
EP3341875A1 (en) * 2015-08-27 2018-07-04 Koninklijke Philips N.V. An integrated method and system for identifying functional patient-specific somatic aberations using multi-omic cancer profiles
KR101944927B1 (ko) 2016-03-24 2019-02-07 서울대학교산학협력단 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
WO2017164699A1 (ko) * 2016-03-24 2017-09-28 서울대학교병원 (분사무소) 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
CN106480211A (zh) * 2016-11-24 2017-03-08 深圳市核子基因科技有限公司 一种用于检测睾丸癌易感性的试剂盒及其snp标志物
WO2018141828A1 (en) * 2017-02-01 2018-08-09 Phadia Ab Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics
WO2020111169A1 (ja) * 2018-11-28 2020-06-04 国立大学法人千葉大学 多因子遺伝疾患の遺伝子検査法、及び検査キット
WO2020223657A1 (en) * 2019-05-02 2020-11-05 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk
WO2021178832A2 (en) * 2020-03-06 2021-09-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Dna damage repair genes in cancer
KR102177222B1 (ko) * 2020-04-24 2020-11-10 유니젠바이오 주식회사 머신러닝 기반 암진단 예측 시스템
KR102177218B1 (ko) * 2020-04-24 2020-11-10 유니젠바이오 주식회사 머신러닝 기반 암진단 예측 장치
KR20250074712A (ko) 2023-11-15 2025-05-28 주식회사 바스젠바이오 전립선암 발병의 위험도를 예측하기 위한 조성물 및 이를 이용한 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
AU785425B2 (en) * 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
CA2460215A1 (en) * 2001-08-04 2003-02-20 Whitehead Institute For Biomedical Research Haplotype map of the human genome and uses therefor
US20040023237A1 (en) * 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US20040146870A1 (en) * 2003-01-27 2004-07-29 Guochun Liao Systems and methods for predicting specific genetic loci that affect phenotypic traits

Also Published As

Publication number Publication date
BRPI0718322A2 (pt) 2013-11-26
JP2010507388A (ja) 2010-03-11
JP5631000B2 (ja) 2014-11-26
NZ576591A (en) 2012-04-27
WO2008050356A1 (en) 2008-05-02
MX2009004522A (es) 2009-07-02
EP2089548A1 (en) 2009-08-19
US20100129799A1 (en) 2010-05-27
AU2007310412A1 (en) 2008-05-02
AU2007310412B2 (en) 2013-02-14
IL198305A0 (en) 2010-02-17
CN101641451A (zh) 2010-02-03
CA2667737A1 (en) 2008-05-02
ZA200903173B (en) 2010-02-24

Similar Documents

Publication Publication Date Title
AU2007310412B2 (en) Cancer susceptibility variants on Chr8q24.21
US8580501B2 (en) Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
US8865400B2 (en) Genetic variants contributing to risk of prostate cancer
US20110117545A1 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
CA2734123A1 (en) Genetic variants predictive of cancer risk
CA2729931A1 (en) Genetic variants predictive of cancer risk in humans
AU2009269542A1 (en) Genetic variants for breast cancer risk assessment
US20110020320A1 (en) Genetic Variants Contributing to Risk of Prostate Cancer
US20140248615A1 (en) Genetic variants on chr 11q and 6q as markers for prostate and colorectal cancer predisposition